Recently, Tucker and colleagues discovered that CENPE inhibitors could overcome resistance to microtubule-binding agents like taxanes by exacerbating CIN to induce breast cancer cell death, nominating this combination as a synergistic therapeutic approach [133]. Here, CENPE is linked to breast carcinoma.